SAN DIEGO, March 16 Organovo, Inc., the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for research and surgical applications, today announced the appointment of Marie Csete, M.D., Ph.D., as Executive Vice President of Research and Development.
Advertisement
"Marie's background is ideally suited for Organovo," said Keith Murphy, the company's Chief Executive Officer. "She has extensive experience in clinical organ transplant and is a leader in the understanding of stem cell behavior. In her previous role, Marie was instrumental in fostering translation of early technologies to practical results. Marie is an excellent fit to lead the company's efforts to move our therapeutic pipeline rapidly to the clinic."
Advertisement
Dr. Csete previously worked as the Chief Scientific Officer of the California Institute for Regenerative Medicine (http://www.cirm.ca.gov/), the state agency formed through statewide ballot measure Proposition 71 in 2004. At CIRM, which has the mandate to broadly support research in regenerative medicine, she oversaw the development of all research programs, grant review, portfolio management and scientific strategy.
Previously, Dr. Csete received her M.D. from Columbia University in New York after completing undergraduate work at Princeton University. She was on the faculty of the medical schools at the University of California San Francisco and the University of California Los Angeles, leading the liver transplant anesthesiology teams at both institutions. Her clinical research work focused on methods to optimize the perioperative care of patients with liver disease. Dr. Csete received a Ph.D. in developmental biology from the California Institute of Technology, where she worked on the role of physiologic gases in stem cell fate. She extended this work into the study of stem cell aging as the John E. Steinhaus Professor of Anesthesiology at Emory University where she directed the liver transplant anesthesia team and was co-Director of the M.D./Ph.D. Program. Additionally, Dr. Csete has served on numerous editorial boards and federal review panels.
About Organovo:
Organovo is a regenerative medicine company focused on delivering breakthrough tissue printing technology and creating tissue on demand for research and surgical applications. As the first company with a three-dimensional tissue technology platform that works across all tissue types, Organovo is helping physicians and researchers fulfill the promise of regenerative medicine. We aim to overcome critical problems in cardiovascular medicine, medical research, and eventually transplant medicine. Organovo technology leads the way in solving complex medical problems with one overarching goal: to benefit the health and lives of our patients. http://www.organovo.com
SOURCE Organovo, Inc.
